Page last updated: 2024-11-06

2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID61215
CHEMBL ID488278
CHEBI ID82394
SCHEMBL ID3789047
MeSH IDM0048081

Synonyms (55)

Synonym
p-benzoquinone, 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-
2,5-bismethoxyethoxy-3,6-bisethyleneimino-1,4-benzoquinone
2,5-bis(methoxyethoxy)-3,6-bis(ethylenimino)-p-benzoquinone
2,5-bis(methoxyethoxy)-3,6-bis(ethyleneimino)-p-benzoquinone
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone
2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-
3,6-bis(beta-methoxyethoxy)-2,5-bis(ethyleneimino)-p-benzoquinone
2,5-bis(1-aziridinyl)-3,5-bis(methoxyethoxy)-p-benzoquinone
ccris 64
2,5-bis(aziridinyl)-3,6-bis(2-methoxyethoxy)quinone
3,6-bis(beta-methoxyethoxy)-2,5-bis(ethylenimino)-p-benzoquinone
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-2,5-cyclohexadiene-1,4-dione
brn 0320574
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-p-benzoquinone
2,5-bis(methoxyethoxy)-3,6-bis(aziridino)-1,4-benzoquinone
2,5-di(methoxyethoxy)-3,6-bis(ethyleneimino)-1,4-benzoquinone
a-139
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-1,4-benzoquinone
ai3-26382
2,6-bis(aziridino)-1,4-benzoquinone
wln: l6v dvj bo2o1 eo2o1 c- at3ntj& f- at3ntj
bay a 139
2,6-bisethyleneimino-1,4-benzoquinone
nsc-17262
aziridyl benzoquinone
3,5-bis(ethyleneimino)-p-benzoquinone
bayer a 139
3,5-bis(ethylenimino)-p-benzoquinone
a 139
benzoquinone aziridine
2,4-dione, 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-
nsc 17262
e 39 soluble
p-benzoquinone,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-
nsc17262
bayer e 39 solubile
bayer e39 soluble
2,6-bis(2-methoxyethoxy)-2,5-cyclohexadiene-1,4-dione
2,6-bis(2-methoxyethoxy)-p-benzoquinone
800-24-8
2,5-bis(aziridin-1-yl)-3,6-bis(2-methoxyethoxy)cyclohexa-2,5-diene-1,4-dione
CHEMBL488278
chebi:82394 ,
SCHEMBL3789047
C19333
unii-g209r93vod
g209r93vod ,
4-20-00-00034 (beilstein handbook reference)
bayer r39
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-1,4-benzoquinone [mi]
bis(1-aziridinyl)-3,5-bis(methoxyethoxy)-p-benzoquinone, 2,5-
DTXSID1074834
AKOS027282670
Q27155917
2,5-diaziridin-1-yl-3,6-bis(2-methoxyethoxy)cyclohexa-2,5-diene-1,4-di one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma decay curves could be fitted to a two-compartment open-system model with an overall average alpha and beta half-life values of 10."( Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Baker, LH; Haas, CD; Leichman, LP; Schilcher, RB; Young, JD, 1983
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Comparison of the slope of the regression line for the dose-response curve and the interpolated ID90 for each drug showed that U251-MG was equally sensitive to aziridinylbenzoquinone and dianhydrogalactitol in all three assays."( Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Berens, ME; Dougherty, DV; Giblin, JR; Hoifodt, HK; Rosenblum, ML; Tveit, K, 1988
)
0.27
" The development of paralysis due to white-matter necrosis in rats of each dose group was scored and dose-response curves were constructed."( Effect of combined AZQ and radiation on the tolerance of the rat spinal cord.
Ang, KK; van der Kogel, AJ; van der Schueren, E, 1986
)
0.27
" However, cumulative thrombocytopenia occurred even in patients without prior nitrosourea therapy and necessitated significant dosage reductions with subsequent cycles."( Phase II study of aziridinylbenzoquinone in refractory lymphoma.
Case, DC; Hayes, DM, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,4-benzoquinonesAny member of the class of benzoquinones that is 1,4-benzoquinone or its C-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (92.31)18.7374
1990's2 (5.13)18.2507
2000's1 (2.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.31 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (5.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]